Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 4
2007 2
2008 2
2010 1
2012 2
2013 4
2014 9
2015 8
2016 7
2017 8
2018 10
2019 10
2020 10
2021 19
2022 20
2023 23
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
Rao VK, Webster S, Šedivá A, Plebani A, Schuetz C, Shcherbina A, Conlon N, Coulter T, Dalm VA, Trizzino A, Zharankova Y, Kulm E, Körholz J, Lougaris V, Rodina Y, Radford K, Bradt J, Kucher K, Relan A, Holland SM, Lenardo MJ, Uzel G. Rao VK, et al. Among authors: dalm va. Blood. 2023 Mar 2;141(9):971-983. doi: 10.1182/blood.2022018546. Blood. 2023. PMID: 36399712 Free PMC article. Clinical Trial.
Human autoinflammatory disease reveals ELF4 as a transcriptional regulator of inflammation.
Tyler PM, Bucklin ML, Zhao M, Maher TJ, Rice AJ, Ji W, Warner N, Pan J, Morotti R, McCarthy P, Griffiths A, van Rossum AMC, Hollink IHIM, Dalm VASH, Catanzaro J, Lakhani SA, Muise AM, Lucas CL. Tyler PM, et al. Among authors: dalm vash. Nat Immunol. 2021 Sep;22(9):1118-1126. doi: 10.1038/s41590-021-00984-4. Epub 2021 Jul 29. Nat Immunol. 2021. PMID: 34326534 Free PMC article.
Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review.
Lamers OAC, Smits BM, Leavis HL, de Bree GJ, Cunningham-Rundles C, Dalm VASH, Ho HE, Hurst JR, IJspeert H, Prevaes SMPJ, Robinson A, van Stigt AC, Terheggen-Lagro S, van de Ven AAJM, Warnatz K, van de Wijgert JHHM, van Montfrans J. Lamers OAC, et al. Among authors: dalm vash. Front Immunol. 2021 Apr 15;12:606099. doi: 10.3389/fimmu.2021.606099. eCollection 2021. Front Immunol. 2021. PMID: 33936030 Free PMC article.
Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
Rao VK, Webster S, Dalm VASH, Šedivá A, van Hagen PM, Holland S, Rosenzweig SD, Christ AD, Sloth B, Cabanski M, Joshi AD, de Buck S, Doucet J, Guerini D, Kalis C, Pylvaenaeinen I, Soldermann N, Kashyap A, Uzel G, Lenardo MJ, Patel DD, Lucas CL, Burkhart C. Rao VK, et al. Among authors: dalm vash. Blood. 2017 Nov 23;130(21):2307-2316. doi: 10.1182/blood-2017-08-801191. Epub 2017 Sep 29. Blood. 2017. PMID: 28972011 Free PMC article.
Interim analysis: Open-label extension study of leniolisib for patients with APDS.
Rao VK, Kulm E, Šedivá A, Plebani A, Schuetz C, Shcherbina A, Dalm VA, Trizzino A, Zharankova Y, Webster S, Orpia A, Körholz J, Lougaris V, Rodina Y, Radford K, Bradt J, Relan A, Holland SM, Lenardo MJ, Uzel G. Rao VK, et al. Among authors: dalm va. J Allergy Clin Immunol. 2024 Jan;153(1):265-274.e9. doi: 10.1016/j.jaci.2023.09.032. Epub 2023 Oct 4. J Allergy Clin Immunol. 2024. PMID: 37797893 Free article.
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Spiera R, et al. Arthritis Rheumatol. 2023 Sep;75(9):1608-1618. doi: 10.1002/art.42510. Epub 2023 Jun 15. Arthritis Rheumatol. 2023. PMID: 37098795 Free article. Clinical Trial.
Hyper-IgE in the allergy clinic--when is it primary immunodeficiency?
Ponsford MJ, Klocperk A, Pulvirenti F, Dalm VASH, Milota T, Cinetto F, Chovancova Z, Rial MJ, Sediva A, Litzman J, Agostini C, van Hagen M, Quinti I, Jolles S. Ponsford MJ, et al. Among authors: dalm vash. Allergy. 2018 Nov;73(11):2122-2136. doi: 10.1111/all.13578. Epub 2018 Oct 2. Allergy. 2018. PMID: 30043993 Review.
Serum immunoglobulins and biomarkers of dementia: a population-based study.
Yaqub A, Khan SR, Vernooij MW, van Hagen PM, Peeters RP, Ikram MA, Chaker L, Dalm VASH. Yaqub A, et al. Among authors: dalm vash. Alzheimers Res Ther. 2023 Nov 7;15(1):194. doi: 10.1186/s13195-023-01333-3. Alzheimers Res Ther. 2023. PMID: 37936180 Free PMC article.
A germline STAT6 gain-of-function variant is associated with early-onset allergies.
Suratannon N, Ittiwut C, Dik WA, Ittiwut R, Meesilpavikkai K, Israsena N, Ingrungruanglert P, Dalm VASH, van Daele PLA, Sanpavat A, Chaijitraruch N, Schrijver B, Buranapraditkun S, Porntaveetus T, Swagemakers SMA, IJspeert H, Palaga T, Suphapeetiporn K, van der Spek PJ, Hirankarn N, Chatchatee P, Martin van Hagen P, Shotelersuk V. Suratannon N, et al. Among authors: dalm vash. J Allergy Clin Immunol. 2023 Feb;151(2):565-571.e9. doi: 10.1016/j.jaci.2022.09.028. Epub 2022 Oct 7. J Allergy Clin Immunol. 2023. PMID: 36216080
Azacytidine Treatment for VEXAS Syndrome.
Raaijmakers MHGP, Hermans M, Aalbers A, Rijken M, Dalm VASH, van Daele P, Valk PJM. Raaijmakers MHGP, et al. Among authors: dalm vash. Hemasphere. 2021 Nov 17;5(12):e661. doi: 10.1097/HS9.0000000000000661. eCollection 2021 Dec. Hemasphere. 2021. PMID: 34805767 Free PMC article. No abstract available.
128 results